Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPV) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPV (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV).
Methods: This phase III, open label, randomised study was conducted in the UK between April 2011 and April 2012. Children due their pre-school dTap-IPV booster vaccination were randomised 2:1 to receive one of two different dTap-IPV vaccines (dTap-IPV or dTap-IPV) with blood sample for immunogenicity assessment just prior and one month after vaccination. Immune responses to diphtheria, tetanus and polio antigens were compared between the study vaccines (inferential comparison). In the absence of an accepted pertussis correlate of protection, the immunogenicity of dTap-IPV vaccine against pertussis was compared with historical pertussis efficacy data (inferential comparison). Safety and reactogenicity of both study vaccines were evaluated.
Results: 387 children were randomised and 385 vaccinated: 255 in the dTap-IPV group and 130 in the dTap-IPV group. Prior to vaccination, ≥76.8% of children had anti-diphtheria and ≥65.5% had anti-tetanus titres above the protection threshold; for pertussis, the pre-vaccination seropositivity rate ranged between 18.1 and 70.6%. Both vaccines were immunogenic with 99.2-100% of children achieving titres above the pre-specified seroprotection/seropositivity thresholds. One serious adverse event not considered as causally related to the study vaccination by the study investigator was reported in the dTap-IPV group.
Conclusion: Non-inferiority of dTap-IPV to dTap-IPV was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old.
Trial Registration: NCT01245049 (ClinicalTrials.gov).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2018.03.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inequalities in uptake of childhood vaccination in England, 2019-23: longitudinal study.
BMJ
December 2024
Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
Objective: To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England.
Design: Longitudinal study.
Setting: General practice data for five vaccines administered to children (first and second doses of the measles, mumps, and rubella vaccine (MMR1 and MMR2, respectively), rotavirus vaccine, pneumococcal conjugate vaccine (PCV) booster, and six-in-one (DTaP/IPV/Hib/HepB) vaccine covering diphtheria, tetanus, pertussis, polio, type b, and hepatitis B) from the Cover of Vaccination Uptake Evaluated Rapidly dataset in England.
Adverse events following immunization with DTaP-IPV (Tetraxim) in school-aged children in Taiwan, 2017-2020.
Vaccine X
December 2024
Department of Pediatrics, MacKay Children's Hospital, Taipei, Taiwan.
Vaccination has been an effective method to prevent and control diphtheria, tetanus, pertussis and polio diseases in infancy and adults for years. To maintain the protective effect, a DTaP-IPV vaccine, Tetraxim, was introduced into Taiwan's national immunization program for children at 5 years of age after primary series vaccination in infancy in October 2017 replacing a Tdap-IPV. To survey the safety of this vaccine, data between 01 October 2017 and 31 December 2020 from two surveillance systems, the Vaccine Adverse Events Reporting System (VAERS) and Vaccine Injury Compensation Program (VICP), were reviewed.
View Article and Find Full Text PDFImproving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care.
Vaccine
January 2025
Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, Yvonne Carter Building, 58 Turner Street, London E1 2AB, UK.
Article Synopsis
- A mixed methods evaluation was conducted to assess a digital call-and-recall tool aimed at improving the timely receipt and equity of MMR and DTaP/IPV vaccinations in North East London, focusing on children eligible from January 2019 to January 2024.
- The findings showed a 5.3% increase in timely first MMR vaccinations (from 77.7% to 81.8%), while DTaP/IPV saw a smaller increase of 0.9%. However, no significant change in inequality was observed.
- Users found the tool helpful for recall but noted challenges such as staff dynamics and unrealistic national targets that hindered its consistent application; further support is needed to maintain improvements.
Seroepidemiology of pertussis immunity in five provinces of China: A population-based, cross-sectional study.
Hum Vaccin Immunother
December 2024
Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China.
This study aimed to evaluate the seroprevalence of and persistence of antibodies following vaccination. We recruited 6060 healthy subjects from five provinces of China during 2017-2018. Serum IgG antibodies against pertussis toxin (anti-PT IgG) and filamentous hemagglutinin (anti-FHA IgG), and serum IgA antibodies against pertussis toxin (anti-PT IgA) were measured by ELISA.
View Article and Find Full Text PDFA literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.
Vaccine X
October 2024
Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands.
National Immunisation Programmes (NIPs) develop historically. Its performance (disease incidences, vaccination coverage) is monitored. Reviewing the schedule as a whole could inform on further optimisation of the programme, i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!